Philip Morris International (PM) is confident in the continued growth of its ZYN oral nicotine pouch brand, particularly in the U.S. market. The company recently expanded its ZYN portfolio with the introduction of ZYN ULTRA, adding over 20 new stock-keeping units (SKUs) in approximately two months. This expansion includes moist-format products and higher nicotine strengths, offering 9 milligram and 11 milligram options, which are significantly higher than the flagship ZYN range of 3 milligrams and 6 milligrams. Philip Morris is also considering a 1.5 milligram option to cater to consumers entering the category at lower strengths.
To enhance consumer value and support market share recovery, Philip Morris is transitioning from 15-pouch cans to 20-pouch cans and adjusting ZYN's historical price premium to a more competitive level. CEO Jacek Olczak noted that the ZYN ULTRA line has been received as expected, though distribution and consumer communication are key due to the extensive portfolio expansion. The company has also launched a new "When It Clicks" campaign and plans increased investment in the brand during the second half of the year.
Despite some market data indicating a slowdown to mid-teens category growth, Philip Morris still projects the U.S. nicotine pouch category to grow at over 20% in the long term. This growth is anticipated to be fueled by consumers transitioning from other oral tobacco products, e-vapor products, and cigarettes. The company also received FDA authorization for 11 ZYN products, including ZYN ULTRA, which strengthens its position in the market and supports scaling production.
Financial analysts have largely responded positively to Philip Morris International's outlook. Several firms have raised their price targets for PM shares, with BTIG Research setting a $221.00 target, UBS Group increasing to $182.00, Morgan Stanley to $215.00, Needham & Company LLC to $215.00, and Barclays to $225.00. The consensus rating from analysts is a "Moderate Buy" with an average price target of $205.89. Philip Morris also raised its 2026 adjusted diluted EPS forecast to $8.35-$8.50, attributing the increase to currency tailwinds.
While the ZYN rollout is strategically favorable, its ultimate impact on earnings will depend on consumer adoption. The company's strategy aims for portfolio symmetry with other market players, providing a broad range of options to attract and retain legal-age adult nicotine consumers. Philip Morris is pleased with recent developments and the regulatory clarity provided by FDA authorizations, which allows for more solid future planning.
